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KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical 33 
isolate recovered in Switzerland in 2019. As compared to KPC-3, KPC-50 shows i) a 34 
three amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277 amino acid 35 
sequence, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to 36 
avibactam, explaining the ceftazidime-avibactam resistance, and (iv) associated to a 37 
sharp reduction of its carbapenemase activity. 38 


































































Occurrence of multidrug-resistant Enterobacterales, and especially of carbapenemase-41 
producing isolates, is increasingly reported, thus leaving very few therapeutic options for 42 
treating related infections (1). Interestingly, the recently-marketed ceftazidime/avibactam 43 
(CZA) drug combination offers novel interesting perspectives (2). This β-lactam/β-lactamase 44 
inhibitor combo provides a therapeutic alternative for treating infections caused by KPC-like 45 
and OXA-48-like producers, whereas producers of carbapenemases of the metallo-ß-46 
lactamase type remain resistant to that combination (1, 2). Despite CZA is still rarely 47 
prescribed worldwide, KPC-like producing isolates being resistant to this drug combo have 48 
been already reported (3-7). Several reports identified KPC variants exhibiting single amino 49 
acid substitutions in their omega-loop (amino acid positions 164-179), and particularly the 50 
Asp179Tyr substitution, leading to enhanced affinity toward ceftazidime, with a concomitant 51 
reduced binding to avibactam (8-12). In addition, we recently identified KPC-41, possessing a 52 
three amino-acid insertion in the KPC-3 protein sequence being distantly located from the 53 
omega loop (namely between positions 269-270), that conferred high level of resistance to 54 


































































K. pneumoniae isolate N869 was recovered from a patient repatriated after a traffic 57 
accident from Greece to Switzerland. In the Greek hospital, the patient developed a ventilator-58 
associated pneumonia for which he received a treatment made of clindamycin, linezolid and 59 
meropenem during two days, to which colistin was added on day 5. Few days later, he was 60 
transferred to Switzerland where all antibiotics but meropenem (as monotherapy then) were 61 
discontinued. Rectal swabs performed at admission grew K. pneumoniae isolate N859 using 62 
the Chrom ID Carba Smart
®
 selective plate (bioMérieux, La Balme-les-Grottes, France). 63 
According to the EUCAST 2020 breakpoints (14), K. pneumoniae isolate N859 was resistant 64 
to all ß-lactams including to imipenem and ertapenem, but remained susceptible to 65 
meropenem (Table 1). The carbapenemase activity was evaluated by using the Rapid Carba 66 
NP test that gave a positive result (15). 67 
K. pneumoniae N859 was also resistant to aminoglycosides (kanamycin, tobramycin, 68 
netilmicin), to fluoroquinolones and to colistin (MIC at 128 µg/ml). It remained susceptible to 69 
tetracycline, tigecycline, chloramphenicol, trimethoprim-sulfamethoxazole and fosfomycin, 70 
and was of intermediate susceptibility to amikacin and gentamicin. It also showed resistance 71 
to CZA (MIC at >256 µg/ml) and to ceftolozane-tazobactam combination (> 256 µg/ml), 72 

































































PCR identified a blaKPC-like gene and sequencing of the corresponding amplicon 74 
identified a gene encoding a KPC variant possessing a three amino-acid insertion (Glu-Ala-75 
Val) between amino acids 276 and 277 (Ambler numbering), leading to a novel variant named 76 
KPC-50 (Figure S1). Search of additional ß-lactamase resistance genes as reported (16) 77 
identified a blaSHV-like gene (intrinsic to K. pneumoniae) but no additional extended-spectrum 78 
ß-lactamase gene. Mating-out assays performed using K. pneumoniae N859 as donor and 79 
azide-resistant Escherichia coli J53 strain as recipient (13) were successful and confirmed the 80 
plasmid location of the blaKPC-50 gene, being ca. 60-kb in-size (data not shown). No other 81 
antibiotic marker was co-transferred along with the blaKPC-50 gene. PCR-based replicon typing 82 
showed that this plasmid belonged to the IncFIB incompatibility group (17). Multilocus 83 
sequence typing performed as described (18) showed that isolate N859 belonged to sequence 84 
type ST258 that corresponds to the worldwide spread KPC-producing K. pneumoniae 85 
background (19, 20).  86 
In order to confirm if the amino acid substitutions identified within the KPC sequence 87 
might be responsible for the CZA resistance phenotype observed in K. pneumoniae N859, the 88 
blaKPC-50 gene was cloned and expressed in E. coli TOP10. MIC values were then compared 89 

































































background, KPC-3 conferred resistance to all β-lactams including ceftazidime, but remained 91 
susceptible to CZA, as previously shown (13). Conversely, although KPC-50 also conferred 92 
high-level resistance to ceftazidime, it additionally conferred high-level of resistance to CZA 93 
(Table 1). Noteworthy, KPC-50 conferred much lower level of resistance to cefoxitin, 94 
cefotaxime and cefepime than KPC-3. One of the most marked features of KPC-50 as 95 
compared to KPC-3 was that its production did not lead to resistance to carbapenems (Table 96 
1). Indeed, E. coli expressing the blaKPC-50 gene remained susceptible to ertapenem and 97 
meropenem (MICs at 0.25 µg/ml and 0.5 µg/ml, respectively), while the MIC of imipenem 98 
observed for that KPC-50-producing E. coli recombinant strain was at 4 µg/ml (breakpoint 99 
value). Low MICs were observed when testing the new carbapenem /ß-lactamase inhibitor 100 
combinations such as imipenem/relabactam, and more specifically meropenem/vaborbactam 101 
that showed an excellent capacity to inhibit the growth of KPC-50 producers (Table 1). 102 
The enzymatic properties of KPC-50 were determined using purified extracts, and 103 
compared to those of KPC-3 previously obtained under same conditions (13). Kinetic data 104 
showed that KPC-50 has a lower hydrolysis activity of cefalotin, cefotaxime, aztreonam and 105 
imipenem, as compared to that of KPC-3 (Table 2). Similar decreased hydrolytic properties 106 

































































to the CZA combination, such as for KPC-41 (13) or the Asp179Tyr KPC-2 mutants (21-23). 108 
Furthermore, the activity of KPC-50 toward aztreonam was not detectable by contrast to 109 
KPC-3 (Table 2), and contrasting also with data obtained for KPC-41 (13). 110 
Kinetic activities toward ceftazidime were measured and compared for KPC-50 and 111 
KPC-3 enzymes. As expected, a significant hydrolysis rate was detected with KPC-3, but no 112 
hydrolysis could be detected with KPC-50 in normal conditions (measurement made during 5 113 
min). Then, another assay was performed during 1 hour, showing that ceftazidime was indeed 114 
hydrolyzed by KPC-50, but the hydrolysis rate was much lower than that of KPC-3 (Figure). 115 
Therefore, we observed here a paradoxical situation with KPC-50 conferring high-level 116 
resistance to ceftazidime once produced by a recombinant E. coli clone, but weak hydrolysis 117 
rate measured by UV spectrophotometry. Thus, compared affinities of KPC-50 and KPC-3 to 118 
the ceftazidime substrate were respectively measured using various concentrations of 119 
ceftazidime, to inhibit the hydrolysis of a reporter substrate (nitrocefin) as published (13, 24). 120 
At the same ceftazidime concentrations, a higher inhibition level of nitrocefin was observed 121 
with KPC-50 than with KPC-3 (Figure), showing that KPC-50 exhibited a higher affinity 122 

































































Comparative inhibitory activity of clavulanic acid, tazobactam and AVI were 124 
determined for KPC-50 and KPC-3, showing a 4-fold lower inhibitory activity of AVI toward 125 
KPC-50 compared to KPC-3, while conversely that of tazobactam and clavulanic acid were 126 
higher toward KPC-50 than KPC-3 (Table 2). 127 
Those results overall indicated that the 276-Glu-Ala-Val-277 insertion observed in the 128 
KPC-50 sequence wa responsible for a reduced hydrolysis of cefalotin, cefotaxime, and 129 
carbapenems, associated to a higher affinity toward ceftazidime and a reduced sensitivity to 130 
AVI.  131 
CONCLUSION 132 
A novel KPC-type enzyme conferring resistance to CZA was identified here from a 133 
multidrug-resistant K. pneumoniae isolate recovered in Switzerland but likely acquired in 134 
Greece, with no known history of treatment with CZA for the patient. Of note, and as already 135 
highlighted for KPC-41 and other KPC mutants conferring resistance to CZA, the overall 136 
decreased carbapenemase activity observed for KPC-50 might be considered as good news. 137 
Furthermore, the newly-developed carbapenem/ß-lactamase inhibitor combinations 138 

































































against the KPC-50 producers (either the K. pneumoniae clinical isolate or the E. coli 140 
recombinant strain). 141 
 142 
The sequence of KPC-50 has been deposited in the NCBI database under the accession 143 
number GenBank MN654342. 144 
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 153 
Figure. Analysis of ceftazidime hydrolysis. (A) KPC-50 and KPC-3 (1 μM enzyme) 154 
hydrolysis of 25 μM ceftazidime (CAZ) at room temperature. (B) and (C) Competitive 155 

































































with 0.1 μM KPC-50 (B) and 0.1 μM KPC-3 (C) at room temperature. For (B) and (C) 157 
nitrocefin absorbance was measured. 158 
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Table 1. MICs of -lactams for K. pneumoniae clinical isolate N859, E. coli TOP10 recombinant 
strains producing KPC-50 and KPC-3, respectively, and E. coli TOP10 recipient strain 
*Clavulanic acid was added at a fixed of 2 µg/ml, tazobactam at 4 µg/ml, avibactam at 4 µg/ml, relabactam at 4 µg/ml, and 
vaborbactam at 8 µg/ml.
ß-lactams*  MICs (µg/ml)    
 K. pneumoniae N859  






Amoxicillin >1,024 >256 >128   8 
Amoxicillin – clavulanic acid  >1,024     64 >128   8 
Ticarcillin >1,024 >256 >128   8 
Ticarcillin – clavulanic acid >1,024     64 >128   8 
Piperacillin >1,024   256 >128   2 
Piperacillin – tazobactam  >1,024   128 >128   2 
Cefalotin >1,024   512 >128 16 
Cefotaxime          8      8 >128 < 0.125
Cefepime          8       8   128 <0.125 
Ceftazidime   2,048 1,024 2,048   0.25 
Ceftazidime – avibactam   >256     64        2   0.25 
Ceftolozane – tazobactam   >256     64 >256   0.06 
Cefoxitin       32       8   128   8 
Aztreonam       32     16     64 <0.125 
Ertapenem         1       0.25     32 <0.125 
Imipenem       16       4     16 <0.125 
Imipenem - relabactam         2       0.5       0.5 <0.125 
Meropenem         2       0.5     16 <0.125 
































































































































Table 2. Kinetic parameters of purified β-lactamases KPC-50 and KPC-3. Data for KPC-3 
correspond to those previously reported (13). Inhibitory concentration 50% (IC50) and kinetic 
inhibition parameters of β-lactamase inhibitors against KPC-50 and KPC-3 (bottom).  
β-Lactam(s)* 
KPC-50  KPC-3 
kcat (s-1) Km (µM) kcat/Km (mM-1.s-1)  kcat (s-1) Km (µM) kcat/Km (mM-1.s-1) 
Benzylpenicillin <0.01 ND ND 5.6 33 0.2 
Cefalotin 2.2 30 0.07 47 113.5 0.4 
Cefotaxime 1.7 55 0.003 34.9 532.8 0.065 
Ceftazidime <0.01 ND ND > 3.3  > 700 > 4.7 E-3 
Aztreonam <0.01 ND ND 5 194.8 0.03 
Imipenem 2 85 0.02 4.7 71.5 0.07 
Meropenem <0.01 ND ND 0.47 18.5 0.03 
Ertapenem <0.01 ND ND  0.58 37 0.02 
            
IC50 (μM)    Ki (μM) 
Inhibitor KPC-50 KPC-3 KPC-50 KPC-3 
Clavulanic acid 10 20 4 20 
Tazobactam 10 50 1 10 
Avibactam 4 1 2 1 
ND : Not determinable due to a low initial rate of hydrolysis 
k
cat
, turnover ; K
m,
, Michaelis constant (affinity); kcat/KM = specificity constant (hydrolysis) 
IC50 represents the concentration of a drug that is required for 50% inhibition of the enzymatic activity 
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